---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-047683"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:45:26.556936+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences completes acquisition of Zynerba for $60M cash plus up to $140M in CVRs

## Summary
- Purchase price of $1.1059 per share in cash (approx. $60M aggregate) plus one CVR per share worth up to $2.5444.
- Tender offer received 52.3% of Zynerba shares; merger completed on Oct 10, 2023; Zynerba now wholly owned subsidiary.
- Lead candidate Zygel is a synthetic cannabidiol gel in Phase 3 for Fragile X syndrome; also studied in 22q deletion syndrome.
- Zygel granted FDA Fast Track for FXS and orphan designation in US and EU; potential to address ~160,000 US patients.
- Zynerba common stock to be delisted from Nasdaq; Harmony diversifies pipeline beyond sleep/wake therapies.

## SEC filing metadata
- accession: 0001140361-23-047683
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/0001140361-23-047683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/ny20012277x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-047683
- JSON: https://secwatch.observer/filing/0001140361-23-047683.json
- Plain text: https://secwatch.observer/filing/0001140361-23-047683.txt

## Key facts
- M&A Transactions
  Harmony Biosciences Holdings, Inc. completed an acquisition involving Zynerba Pharmaceuticals, Inc. for $1.1059 per Share in cash plus one contingent value right per Share (closed 2023-10-10).
  - Action: acquisition
  - Counterparty: Zynerba Pharmaceuticals, Inc.
  - Consideration: $1.1059 per Share in cash plus one contingent value right per Share
  - Closing: 2023-10-10
  source text: commenced a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Zynerba , par value $0.001 per share (the “Shares”), at a price of (i) $ 1.1059 per Share (the “Closing Amount”), in cash, subject to any applicable withholding of taxes and without interest, plus (ii) one contingent value right (each, a “CVR”) per Share ,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/0001140361-23-047683-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.